A phase II, multicenter, randomized, open-label study to evaluate the safety and efficacy of 400 mg of ribociclib in combination with non-steroidal aromatase inhibitors for the treatment of pre- and postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received no prior therapy for advanced disease

Authors
Category Primary study
Registry of TrialsClinical Trials Peruvian Registry
Year 2019
This article has no abstract
Epistemonikos ID: 0c9ab6a9d13fa9f9f1c30be166614c8a5de9683c
First added on: Apr 11, 2025